BioLife Solutions vs Haemonetics
Haemonetics reported revenue of $1.3 billion in fiscal 2026, 13.9 times BioLife Solutions' $96 million in fiscal 2025. BioLife Solutions' revenue grew 28.9% in its latest year, and Haemonetics' fell 2.0%. BioLife Solutions had an operating margin of -17.3%, against 11.8% at Haemonetics. Free cash flow was $11 million at BioLife Solutions and $260 million at Haemonetics. Their fiscal years end in different months (December 31 and March 28), so the periods don't line up exactly.
Side by side
| BioLife Solutions | Haemonetics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2026, Mar 28, 2026 |
| Revenue | $96M | $1.3B |
| Revenue growth | 28.9% | −2.0% |
| Revenue growth a year, last 5 years | 14.9% | 8.9% |
| Gross margin | 64.6% | 59.0% |
| Operating margin | −17.3% | 11.8% |
| Net margin | −4.8% | 7.3% |
| Free cash flow | $11M | $260M |
| Free cash flow margin | 11.1% | 19.5% |
| Return on capital | −4.8% | 6.7% |
| Net debt to EBITDA | — | 3.7x |
| Dividends and buybacks | $0M | $175M |
| Change in diluted share count | 5.6% | −6.7% |
| Last close | — | $119.19 |
| P/E at the last close | — | 57.6× |
| Insider trades, last 12 months | sold $34.0 million | bought $98,784, sold $0 |
| Piotroski F-score | 6 of 9 | 7 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
BioLife SolutionsHaemonetics
Operating margin
Percent of revenue
BioLife SolutionsHaemonetics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
BioLife SolutionsHaemonetics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the BioLife Solutions and Haemonetics pages.